Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 181.46

-2.4%

Feb 12 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Cheryl Galt who wrote (28290)	2/21/1999 12:05:00 PM
From: aknahow	Read Replies (2) of 32384

" ... the return of Targretin rights will now permit us to rapidly generate revenues from distribution agreements pending in territories in which we will not directly market Targretin in oncology and dermatology,'' said Ligand Chairman, President and CEO David E. Robinson. " Robinson has just said LGND has pending agreements to sell Targretin in countries, or geographic zones where it will not be sold by LGND for cancer or dermatology. Since I have no idea of where these areas are, nor what it can be rapidly sold for, if PENDING agreements are finalized, I still do not know how much weight to place on this statement, nor how to value the unknown revenues, from an unknown spot on the map, for an unknown use. But, I understand the statement.<g>

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next